Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT01026844
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Chinese Society of Lung Cancer
- Target Recruit Count
- 256
- Registration Number
- NCT01024413
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- OSI Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT01010945
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Desert Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 51
- Registration Number
- NCT01009073
- Locations
- 🇺🇸
Site Reference ID/Investigator# 37463, Santa Monica, California, United States
🇺🇸Site Reference ID/Investigator# 36342, Detroit, Michigan, United States
🇺🇸Site Reference ID/Investigator# 24046, San Antonio, Texas, United States
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 13
- Registration Number
- NCT01009203
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States
Erlotinib for Treatment of Psoriasis
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT01006096
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 6
- Registration Number
- NCT01003938
- Locations
- 🇺🇸
Bellevue Hospital Center, New York, New York, United States
🇺🇸NYU Clinical Cancer Center, New York, New York, United States
🇺🇸Tisch Hospital, New York, New York, United States
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 9
- Registration Number
- NCT00998036
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- David M. Jackman, MD
- Target Recruit Count
- 60
- Registration Number
- NCT00997334
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 4
- Registration Number
- NCT00996502
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.